The shares were purchased at an average price of $5.50 per share, for a total transaction of $55,000.00. In other news, Director Gordon Tunstall bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 1st. The company has a 50-day moving average of $4.49 and a two-hundred day moving average of $9.08. The stock has a market cap of $59.46 million, a PE ratio of -0.62 and a beta of 1.55. The company has a current ratio of 3.79, a quick ratio of 3.73 and a debt-to-equity ratio of 10.40. Tabula Rasa HealthCare has a 12-month low of $2.16 and a 12-month high of $53.38. Shares of Tabula Rasa HealthCare stock opened at $2.30 on Friday. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $14.53. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the company. Finally, Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research report on Tuesday, May 3rd. lowered shares of Tabula Rasa HealthCare from a “hold” rating to a “sell” rating in a research report on Friday, May 13th. SVB Leerink dropped their target price on shares of Tabula Rasa HealthCare from $23.00 to $11.00 and set a “market perform” rating for the company in a report on Monday, February 28th. Baird cut shares of Tabula Rasa HealthCare from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $24.00 to $11.00 in a report on Tuesday, February 1st. Benchmark dropped their target price on shares of Tabula Rasa HealthCare from $30.00 to $15.00 and set a “buy” rating for the company in a report on Wednesday, March 2nd. Get Tabula Rasa HealthCare alerts:Ī number of research analysts have issued reports on the stock. Zacks’ sales averages are a mean average based on a survey of research firms that follow Tabula Rasa HealthCare. For the next financial year, analysts expect that the company will post sales of $355.59 million, with estimates ranging from $304.50 million to $423.70 million. The firm is scheduled to issue its next earnings report on Monday, January 1st.Īccording to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year sales of $316.62 million for the current fiscal year, with estimates ranging from $278.03 million to $355.20 million. Tabula Rasa HealthCare posted sales of $82.31 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 4.9%. The highest sales estimate is $92.10 million and the lowest is $67.21 million. Four analysts have issued estimates for Tabula Rasa HealthCare’s earnings. ( NASDAQ:TRHC – Get Rating) will report $78.29 million in sales for the current fiscal quarter, according to Zacks. Analysts forecast that Tabula Rasa HealthCare, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |